Compare Citius Pharmaceuticals Inc (CTXR) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares MSCI Indonesia ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while iShares MSCI Indonesia ETF trades at $12. The key difference: iShares MSCI Indonesia ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | EIDO | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | — |
52-Week High | $1.82 | $19.22 |
52-Week Low | $0.53 | $10.80 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
EIDO trades at $11.98, up 1.1% today, but technical indicators signal a bearish trend with moving averages and RSI_6 suggesting caution. The ETF's dividend was cut by 27% in 2025, reflecting underlying pressures. Recent news highlights Indonesia's economic initiatives, including AI integration in government programs, which could boost GDP but face currency volatility from Bank Indonesia's rate hikes to defend the rupiah.
Outlook remains mixed: potential growth from Indonesia's economic policies offers opportunity, but risks from currency instability and dividend reductions weigh on investor confidence. The bearish technical setup and lack of recent fundamental data necessitate careful evaluation of emerging market exposure amid global macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
